xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

360

KUANetal.

TABLE XXXII.3 Evidence surrounding QOL After radiation therapy for SNM.

Clinical endpoints Treatment toxicities

Study

Year LOE Study design Study groups

Conclusion

Patel et al. 458

1. Patients treated with charged particle therapy experienced more neurological toxic effects than those treated with photon therapy 2. There was no significant difference in other toxic effects 1. 10% of patients had major surgical complications, including seroma, wound infection, fistula, and hemorrhage 2. Mucositis, xerostomia, taste alteration, and dermatitis were the most common low-grade RT toxicities 3. 21% had grade 3 + acuteRT toxicity, including dysphagia or mucositis and dermatologic, wound, ocular, and auditory toxicity 4. After RT, 20% of patients had CRS requiring surgery 1. No patients experienced grade 4 or 5AEs 2. The most common grade 2 or 3 AEs were pain, weight loss, 1. Patients showed worse fatigue, lack of appetite, and drowsiness on the MDASI and physical function on the ASBQ at the end of treatment versus baseline, but these returned to baseline at subsequent follow-up 2. There was no difference in scores for patients treated with fractionated RT and stereotactic RT 1. The most common grade 1–2 toxicities were dermatitis and xerostomia 2. 10% of patients experienced grade 3 acute toxicities, most commonly dysphagia, and 2% experienced grade 3 late toxicities 3. There were no grade 4 or 5 toxicities fatigue, rash, dermatitis, mucositis, dysphagia, and xerostomia

Patients with SNM

2014 2

Systematic

treated with photon therapy ( n = 1186) or charged particle therapy ( n = 286)

reviewand meta analysis of observa tional studies

Patel et al. 476

2020 3

Retrospective cohort

129 patients treated for primary SNM

Posttreatment

complications andRT toxicity

Adeberg

1. Grade 2/3 CTCAEs 2. Grade 4/5 CTCAEs

2020 3

Prospective cohort

23 patients with head and neck ACC receiving cetuximab and carbon ion boost followed by IMRT

et al. 2145

Bahig et al. 443

2020 3

Prospective cohort

39 patients receiving

Score on the

re-RT for a recurrent or new skull base tumor

MDASI and ASBQ pretreatment and at various points posttreatment

Fanet al. 2147

Treatment toxicities

2020 3

Retrospective cohort

166 patients with

recurrent head and neck cancer and previous RT treated

with palliative quad-shot RT

(Continues)